Net operating loss

Lands’ End Announces First Quarter 2024 Results

Retrieved on: 
Mercoledì, Giugno 5, 2024
Online, Acquisition, Inventory, Net operating loss, GMV, Capital expenditure, End, International, Delta Air Lines, Growth, Kid, Share repurchase, Third party, Video game

DODGEVILLE, Wis, June 05, 2024 (GLOBE NEWSWIRE) -- Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the first quarter ended May 3, 2024.

Key Points: 
  • DODGEVILLE, Wis, June 05, 2024 (GLOBE NEWSWIRE) -- Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the first quarter ended May 3, 2024.
  • In the first quarter of 2024, GMV increased low single digits compared to the first quarter of 2023.
  • Outfitters Net revenue was $42.7 million for first quarter of fiscal 2024, a decrease of $31.3 million or 42.3% from $74.0 million during the first quarter of fiscal 2023.
  • Adjusted EBITDA was $11.6 million in the first quarter of fiscal 2024 compared to $19.5 million in the first quarter of fiscal 2023.

Arq Reports First Quarter 2024 Results

Retrieved on: 
Mercoledì, Maggio 8, 2024
Carbon, GAC, Sale, PFAS, EPA, Drinking water, Investment, Capital, Red, Research, Depreciation, Yoy, Hand, Capital expenditure, Public expenditure, Net operating loss, Steel, Acquisition, Operating cost, Adjustment, ASP, GAAP, Growth, Interest

GREENWOOD VILLAGE, Colo., May 08, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter ended March 31, 2024.

Key Points: 
  • Red River expansion remains on schedule for first production in Q4 2024; expected payback of 3 years or less
    GREENWOOD VILLAGE, Colo., May 08, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purification and sustainable materials, today announced its financial and operating results for the quarter ended March 31, 2024.
  • Average selling price for the first quarter of 2024 was up approximately 16% compared to prior year period, marking the fourth consecutive quarter of double-digit year-over-year percentage growth in ASP.
  • Gross margin improved to 37% for the first quarter of 2024, compared to 17% in the prior year period.
  • Income tax expenses were zero in the first quarter of 2024, compared to negligible amounts in the prior year period.

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

Retrieved on: 
Mercoledì, Maggio 8, 2024
Radiology, Pharmaceutical, Research, Oncology, Software, Medical Devices, Hospitals, Genetics, Data Management, Stem Cells, Science, Practice Management, Technology, Clinical Trials, Medical Supplies, FDA, Biotechnology, Surgery, Health, CO, Cancer, Depreciation, Webcast, DdPCR, Forecasting, Growth, MSKCC, Net operating loss, Patient, COVID-19, Acquisition, Adjustment, AACR, Bank statement, EGFR, GAAP, AstraZeneca

In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.

Key Points: 
  • In the first quarter, we delivered approximately 11,900 Lung Diagnostic tests, an increase of 57% over the prior year comparable period and our seventh consecutive quarter of greater than 50% year-over-year volume growth.
  • Our team is off to a strong start, helping to impact more patients every quarter in the large and underserved lung nodule diagnostic testing market.
  • Record quarterly gross profit margin of 79% versus 65% for the first quarter 2023 and 77% for the fourth quarter of 2023.
  • The Company reaffirms its 2024 financial outlook and expects to generate between $65 million and $68 million in total revenue in 2024.

OUTFRONT Media Reports First Quarter 2024 Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Corporation, Rotation, International, Travel, Insurance, MTA, Administration, Public expenditure, FFO, Net operating loss, Transit, Outfront Media, Adjustment, Letter, Music

Reported revenues of $408.5 million increased $12.7 million, or 3.2%, for the first quarter of 2024 as compared to the same prior-year period.

Key Points: 
  • Reported revenues of $408.5 million increased $12.7 million, or 3.2%, for the first quarter of 2024 as compared to the same prior-year period.
  • Net Loss Attributable to OUTFRONT Media Inc.
    Net loss attributable to OUTFRONT Media Inc. decreased $1.7 million, or 5.9%, in the first quarter of 2024 compared to the same prior-year period.
  • Net loss attributable to OUTFRONT Media Inc. per common share for diluted earnings per weighted average share was $0.18 in the first quarter of 2024 compared to $0.19 in the same prior-year period.
  • We will host a conference call to discuss the results on May 2, 2024, at 4:30 p.m. Eastern Time.

Sow Good Reports Strong Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Venerdì, Marzo 22, 2024
Cracker Barrel, Target, Gateway Group, Partnership, Candy, Acquisition, Table, Stock, Net operating loss, Adjustment, SKU, GAAP, OTCQB, Video game

IRVING, Texas, March 22, 2024 (GLOBE NEWSWIRE) -- Sow Good Inc. (OTCQB: SOWG) (“Sow Good” or “the Company”), a trailblazer in the freeze dried candy and treat industry, is reporting financial and operating results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • “Our strong 2023 results reflect our swift momentum and progress as a first mover in the freeze dried candy space,” said Claudia Goldfarb, CEO of Sow Good.
  • Same Year-Ago Quarter
    Revenue in the fourth quarter of 2023 increased significantly to $9.5 million compared to $47.1 thousand in the fourth quarter of 2022.
  • Operating expenses in the fourth quarter of 2023 were $1.6 million compared to $6.4 million in the fourth quarter of 2022.
  • Sow Good will conduct a conference call today at 10:00 A.M. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2023.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Mercoledì, Marzo 13, 2024
Administration, Patient, Regulatory affairs, Research, G&A, EMA, Doctor of Philosophy, DM1, Completeness, Health Canada, Senior, Net operating loss, IND, MHRA, Research and development, Duchenne muscular dystrophy, Clinical trial, Data management, Therapy, Vertex Pharmaceuticals, FDA, DMD, Medication, Pharmaceutical industry

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company today reported financial results for the fourth quarter and full year ending December 31, 2023, and highlighted recent business updates.

Key Points: 
  • The Company today reported financial results for the fourth quarter and full year ending December 31, 2023, and highlighted recent business updates.
  • “We continue to make significant progress advancing our growing pipeline of intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
  • Collaboration Revenue: Collaboration revenue was $41.8 million for the fourth quarter of 2023 and $129.0 million for the full year of 2023.
  • The G&A expenses in the fourth quarter of 2023 were lower than the fourth quarter of 2022 primarily due to a decrease in legal and consulting fees.

illumin Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Giovedì, Marzo 7, 2024
Investment, TSX, Growth, Adjustment, Entrepreneurship, Human, Income tax, Net operating loss, Video game

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Self-service revenue growth was driven by an increase in new illumin self-service customers and higher illumin self-service platform utilization.
  • illumin self-service revenue was $8.9 million in the quarter, up 75% from $5.1 million in the prior quarter and up 271% versus Q4 2022.
  • This represented 24% of revenue in the fourth quarter, up from 6% in the prior year period, and was driven largely by new customer relationships and by increased illumin platform utilization.
  • The Company onboarded 33 net new illumin self-service clients during the quarter similar to the prior quarter, reflecting sales initiatives targeting higher-spend clients and positioning the Company for further illumin self-service revenue growth in Q1 2024 on a year-over-year basis.

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Retrieved on: 
Venerdì, Marzo 1, 2024
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Total, Forecasting, Marketing, Growth, COVID-19 testing, GAAP, COVID-19, Webcast, COVID, Patient, Lung cancer, Bank statement, Net operating loss, Research, Depreciation, Pharmaceutical industry

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year ended December 31, 2023 (fiscal 2023).
  • “I am exceptionally proud of the Biodesix team and our record of accomplishments in 2023,” said Scott Hutton, CEO of Biodesix.
  • I am very pleased with our significant progress on each of these goals.”
    Mr. Hutton continued, “The Biodesix team delivered 65% growth in Lung Diagnostic test volume for the full year 2023 and a sixth straight quarter of over 50% year-over-year growth, with the fourth quarter FY23 growing 54% over the fourth quarter of FY22.
  • Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP).

HealthLynked Announces Q3 & Year-to-Date 2023 Financial Results, Highlighted by 8% Revenue Growth and Net Income Turnaround

Retrieved on: 
Mercoledì, Novembre 15, 2023
Sale, Yoy, Collection, YTD, ARI, Partnership, Health, Net operating loss, Life insurance, Pharmaceutical industry, Airline

NAPLES, FL, Nov. 15, 2023 /PRNewswire/ -- HealthLynked Corp. (OTCQB: HLYK), a leader in the global healthcare network industry, announced its financial reporting for the quarter and nine-month period ending September 30, 2023.  The nine-month period was marked by revenue growth, operational efficiency, and a move toward profitability.

Key Points: 
  • HealthLynked Announces Q3 & Year-to-Date 2023 Financial Results, Highlighted by 8% Revenue Growth and Net Income Turnaround
    NAPLES, FL, Nov. 15, 2023 /PRNewswire/ -- HealthLynked Corp .
  • Revenue Increase: Achieved an 8% year-over-year (YoY) increase, totaling $4.796 million, compared to $4.45 million in the same period of 2022.
  • Revenue growth was fueled by additional concierge fees and a steady increase in core technology subscription revenue.
  • Dramatic Net Loss Reduction: A 90% decrease in net loss from $1.78 million Q3 2022 to $0.17 million in Q3 2023, underscoring the effectiveness of our recent strategic initiatives.

SuperCom Reports 550% YoY EBITDA Growth and 5-Year-Record Net Profit for the Third Quarter 2023

Retrieved on: 
Martedì, Novembre 14, 2023
Ministry, EBITDA, Violence, Internet of things, GPS, Domestic violence, Capital, Compare Group, Computer security, Ordane Kanda-Kanyinda, Partnership, E-government, Interior, Net operating loss, House arrest, Growth, Tag (metadata), TEL, Ministry of home affairs, Companding, Working capital, LCA, Cryptocurrency, Tourism, Video game, Airline, Renewable energy, EM

TEL AVIV, Israel, Nov. 14, 2023 /PRNewswire/ -- SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT, and Cybersecurity sectors, today reported financial and operating results for the three and nine months ended September 30, 2023. 

Key Points: 
  • Third Quarter Ended September 30, 2023, Financial Highlights (Compared to the Third Quarter of 2022)
    Revenue increased to $6.8 million from $6.3 million, marking a fifth consecutive quarter of year-over-year ("YoY") revenue growth.
  • Net Income improved 107% to $0.15 million compared to Net Loss of ($2.2) million.
  • Non-GAAP Net Profit improved 256% to $1.6 million compared to Net Loss ($1.0) million.
  • A 5-year record net profit, remarkable 550% growth in EBITDA and 74% growth in gross profit margins are clear indicators of the successful execution of our growth strategy.